These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 29156500)

  • 1. The summary test tradeoff: a new measure of the value of an additional risk prediction marker.
    Baker SG
    Stat Med; 2017 Dec; 36(28):4491-4494. PubMed ID: 29156500
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluating a new marker for risk prediction using the test tradeoff: an update.
    Baker SG; Van Calster B; Steyerberg EW
    Int J Biostat; 2012 Mar; 8(1):. PubMed ID: 22499728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Graphical assessment of incremental value of novel markers in prediction models: From statistical to decision analytical perspectives.
    Steyerberg EW; Vedder MM; Leening MJ; Postmus D; D'Agostino RB; Van Calster B; Pencina MJ
    Biom J; 2015 Jul; 57(4):556-70. PubMed ID: 25042996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating a new marker for risk prediction: decision analysis to the rescue.
    Baker SG; Kramer BS
    Discov Med; 2012 Sep; 14(76):181-8. PubMed ID: 23021372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measures to summarize and compare the predictive capacity of markers.
    Gu W; Pepe M
    Int J Biostat; 2009 Oct; 5(1):Article 27. PubMed ID: 20224632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of risk prediction models in cardiovascular disease research.
    Cui J
    Ann Epidemiol; 2009 Oct; 19(10):711-7. PubMed ID: 19628409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Notes on the overlap measure as an alternative to the Youden index: How are they related?
    Samawi HM; Yin J; Rochani H; Panchal V
    Stat Med; 2017 Nov; 36(26):4230-4240. PubMed ID: 28809042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The need for reorientation toward cost-effective prediction: comments on 'Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond' by Pencina et al., Statistics in Medicine (DOI: 10.1002/sim.2929).
    Chi YY; Zhou XH
    Stat Med; 2008 Jan; 27(2):182-4. PubMed ID: 17712782
    [No Abstract]   [Full Text] [Related]  

  • 9. Using treatment-tradeoff preferences to select diagnostic strategies: linking the ROC curve to threshold analysis.
    DeNeef P; Kent DL
    Med Decis Making; 1993; 13(2):126-32. PubMed ID: 8483397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The need for reorientation toward cost-effective prediction: comments on 'Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond' by M. J. Pencina et al., Statistics in Medicine (DOI: 10.1002/sim.2929).
    Greenland S
    Stat Med; 2008 Jan; 27(2):199-206. PubMed ID: 17729377
    [No Abstract]   [Full Text] [Related]  

  • 11. Review and comparison of ROC curve estimators for a time-dependent outcome with marker-dependent censoring.
    Blanche P; Dartigues JF; Jacqmin-Gadda H
    Biom J; 2013 Sep; 55(5):687-704. PubMed ID: 23794418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve.
    Cook NR
    Clin Chem; 2008 Jan; 54(1):17-23. PubMed ID: 18024533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations.
    Moses LE; Shapiro D; Littenberg B
    Stat Med; 1993 Jul; 12(14):1293-316. PubMed ID: 8210827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating prediction models in reproductive medicine.
    Coppus SF; van der Veen F; Opmeer BC; Mol BW; Bossuyt PM
    Hum Reprod; 2009 Aug; 24(8):1774-8. PubMed ID: 19395365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ROC curves with multiple marker measurements.
    Murtaugh PA
    Biometrics; 1995 Dec; 51(4):1514-22. PubMed ID: 8589236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receiver operating characteristic curve analysis of clinical risk models.
    Grunkemeier GL; Jin R
    Ann Thorac Surg; 2001 Aug; 72(2):323-6. PubMed ID: 11515859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Youden Index and the optimal threshold for markers with mass at zero.
    Schisterman EF; Faraggi D; Reiser B; Hu J
    Stat Med; 2008 Jan; 27(2):297-315. PubMed ID: 17624866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic ROC curves: a method for representing the overall discriminative capacity of binary markers with right-censored time-to-event endpoints.
    Combescure C; Perneger TV; Weber DC; Daurès JP; Foucher Y
    Epidemiology; 2014 Jan; 25(1):103-9. PubMed ID: 24240658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Australian risk prediction model for 30-day mortality after isolated coronary artery bypass: the AusSCORE.
    Reid C; Billah B; Dinh D; Smith J; Skillington P; Yii M; Seevanayagam S; Mohajeri M; Shardey G
    J Thorac Cardiovasc Surg; 2009 Oct; 138(4):904-10. PubMed ID: 19660369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative summary indices for the receiver operating characteristic curve.
    Lee WC; Hsiao CK
    Epidemiology; 1996 Nov; 7(6):605-11. PubMed ID: 8899386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.